StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca koselugo (selumetinib) — Emerging Markets YoY CER (%) (%)

Form 6-K / 20-F Product Sales Table

QuarterlyAnnual
Latest, Q2 2026
45.0%
Period ended Jun 30, 2026
Change on a year earlier
-5.0 pts
50.0% in Q2 2025
History
13 quarters
Since Q4 2020
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKoselugo (selumetinib) — Emerging Markets YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 202645.0%-5.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202639.0%+66.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-44.0%–Form 6-K FY2025Q4 Earnings Release ↗
Q2 2025Jun 30, 202550.0%-30.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-27.0%–Form 6-K FY2025Q1 Earnings Release ↗
Q2 2024Jun 30, 202480.0%+42.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q3 2023Sep 30, 202369.0%–Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202338.0%–Form 6-K FY2023Q2 Earnings Release ↗
Q4 2021Dec 31, 20210.0%0.0 ptsForm 6-K FY2021Q4 Earnings Release ↗
Q3 2021Sep 30, 20210.0%–Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021Jun 30, 20210.0%–Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021Mar 31, 20210.0%–Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020Dec 31, 20200.0%–Form 6-K FY2020Q4 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Koselugo (selumetinib) — Emerging Markets YoY CER (%) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_koselugo_em_cer_yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.